Nektar Therapeutics
Clinical trials sponsored by Nektar Therapeutics, explained in plain language.
A biopharmaceutical company developing polymer-based drug conjugates.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug aims to calm severe eczema without steroids
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Phase 3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New shot could tame tough eczema by calming overactive immune cells
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Phase 3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC